Human-derived antibody targeting pancreatic islet amyloid for the treatment of type 2 diabetes by Hugentobler, Leoni
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
Human-derived antibody targeting pancreatic islet amyloid for the
treatment of type 2 diabetes
Hugentobler, Leoni
Abstract: Type 2 diabetes (T2DM) is one of the most important public health challenges in humans. One
of the hallmarks of T2DM is the deposition of islet amyloid derived from islet amyloid polypeptide (IAPP)
in pancreatic islets. Amyloidogenesis involves the stepwise aggregation of IAPP monomers into oligomers,
fibrils and, ultimately, mature amyloid deposits. The small toxic IAPP oligomers seem to cause ￿-cell
failure and death. None of the available treatments against T2DM counteracts the aggregation of IAPP
and the subsequent loss of pancreatic ￿-cells. A human-derived antibody NI-203.26C11, which targets
human IAPP aggregates was identified, cloned and characterized in vitro and in vivo. Because rat IAPP
is not amyloidogenic, transgenic rats with the human IAPP gene (hIAPP, RIPHAT rats) were used.
NI-203.26C11 significantly improved glucose tolerance and ￿-cell function, increased insulin secretion and
pancreatic insulin content, reduced fasting glucose and normalized body weight in NI-203.26C11-treated
RIPHAT rats compared to controls. In a dose-response study, three different doses of NI-203.26C11
(1, 3, 10 mg/kg) were found to be safe and effective in slowing the progression of T2DM. Interestingly,
1 mg/kg and 10 mg/kg were generally more effective than 3 mg/kg in improving glucose tolerance and
insulin secretion. The lower dose even normalized body weight gain. As conclusion, passive immunization
targeting IAPP aggregates is a very promising approach to treat T2DM.
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-140872
Published Version
Originally published at:
Hugentobler, Leoni. Human-derived antibody targeting pancreatic islet amyloid for the treatment of type
2 diabetes. 2017, University of Zurich, Vetsuisse Faculty.
Institut für Veterinärphysiologie 
der Vetsuisse-Fakultät der Universität Zürich 
Direktor: Prof. Dr. Max Gassmann 
Arbeitsgruppe: Prof. Dr. Thomas A. Lutz 
Arbeit unter wissenschaftlicher Betreuung von 
Dr. PhD Melania Osto 
Human-derived antibody targeting pancreatic islet amyloid 
for the treatment of type 2 diabetes 
Inaugural-Dissertation 
zur Erlangung der Doktorwürde der 
Vetsuisse-Fakultät Universität Zürich 
vorgelegt von 
Leoni Hugentobler 
Tierärztin 
von Uzwil, St. Gallen 
genehmigt auf Antrag von 
Prof. Dr. Thomas A. Lutz, Referent 
PD Dr. PhD Eric Zini, Korreferent 
Zürich 2017 

Meinen Eltern Lilly und Nick, 
sowie meinem Partner Oliver. 
Ich danke euch von Herzen  
für die grossartige Unterstützung während meiner Doktorarbeit  
und dafür, dass ihr immer an mich glaubt und für mich da seid. 
Ohne euch wäre ich niemals Tierärztin geworden. 
Table of content 
1 Zusammenfassung ........................................................................................................ 6 
2 Summary ....................................................................................................................... 7 
3 Introduction .................................................................................................................. 8 
3.1 Epidemiology and risk factors of type 2 diabetes mellitus (T2DM) ................................... 8 
3.2 Pathogenesis of T2DM ........................................................................................................ 8 
3.2.1 Insulin secretion ........................................................................................................... 9 
3.2.2 Insulin action .............................................................................................................. 10 
3.2.3 Insulin resistance ........................................................................................................ 10 
3.2.4 β-cell dysfunction in obesity and T2DM .................................................................... 10 
3.3 Islet amyloid polypeptide (IAPP) or amylin ..................................................................... 11 
3.3.1 Differences between species....................................................................................... 12 
3.4 Pancreatic islet amyloid ..................................................................................................... 12 
3.4.1 Islet amyloid formation .............................................................................................. 14 
3.4.2 β-cell dysfunction due to islet amyloid ...................................................................... 15 
3.4.2.1 Apoptosis ............................................................................................................ 15 
3.4.2.2 Mechanisms activating the intrinsic pathway..................................................... 15 
3.4.2.3 Mechanisms activating the extrinsic pathway .................................................... 17 
3.5 Rodent models of T2DM ................................................................................................... 18 
3.5.1 hIAPP transgenic models ........................................................................................... 19 
3.6 Anti-amyloid treatment ..................................................................................................... 20 
3.6.1 Aromatic organic compounds..................................................................................... 21 
3.6.2 Unmodified short peptides ......................................................................................... 21 
3.6.3 Modified short peptides .............................................................................................. 22 
3.6.4 Flavonoids and other strategies .................................................................................. 22 
3.6.5 Immunotherapy .......................................................................................................... 23 
3.7 Preliminary data ................................................................................................................ 24 
3.7.1 Mouse study ............................................................................................................... 24 
3.7.2 Rat study I (HIP1) ...................................................................................................... 25 
3.7.3 Rat study II (HIP2) ..................................................................................................... 26 
4 Aim of the study .......................................................................................................... 28 
5 Material and Methods ............................................................................................... 29 
5.1 Animals and housing conditions ....................................................................................... 29 
5.2 Study design ...................................................................................................................... 29 
5.2.1 Injection protocol ........................................................................................................ 29 
5.2.2 Human anti-IAPP antibodies ....................................................................................... 30 
5.2.3 Oral Glucose Tolerance Test (oGTT) ......................................................................... 34 
5.2.4 Plasma and pancreas sampling .................................................................................... 34 
5.3 Statistics ............................................................................................................................ 34 
6 Results ......................................................................................................................... 36 
6.1 Animals ............................................................................................................................. 36 
6.2 Body weight ...................................................................................................................... 37 
6.3 Fasting blood glucose and insulin levels ........................................................................... 38 
6.3.1 Fasting glucose levels ................................................................................................. 38 
6.3.2 Fasting insulin levels ................................................................................................... 40 
6.4 Blood levels during the oGTTs ......................................................................................... 43 
6.4.1 Glucose levels ............................................................................................................. 43 
6.4.2 Insulin levels ............................................................................................................... 48 
7 Discussion ................................................................................................................... 52 
8 References ................................................................................................................... 58 
9 Figures and Tables ..................................................................................................... 65 
9.1 Figures ............................................................................................................................... 65 
9.2 Tables ................................................................................................................................ 66 
10 Acknowledgement .................................................................................................... 67 
11 Curriculum Vitae ..................................................................................................... 69 
Zusammenfassung 
1 Zusammenfassung 
Typ 2 Diabetes (T2DM) ist weltweit eine der häufigsten Erkrankungen des Menschen. 
Ein typisches Merkmal des T2DM sind Amyloid Ablagerungen im Pankreas, die aus 
dem sog. "Islet Amyloid Polypeptide" (IAPP) bestehen und deren Bildung stufenweise 
über die Aggregation von IAPP Monomeren zu Oligomeren und Fibrillen abläuft. 
Toxische IAPP Oligomere sind wahrscheinlich für Funktionsstörungen der β-Zellen und 
letztlich deren Zelltod verantwortlich. Keine der momentan verfügbaren T2DM-
Behandlungen richtet sich gegen die Aggregation von IAPP. Ein Antikörper (NI-
203.26C11), welcher humane IAPP Aggregate bindet, wurde in vitro und in vivo 
identifiziert, geklont und charakterisiert. Da IAPP von Ratten nicht amyloidogen ist, 
wurden transgene Ratten verwendet, die das humane IAPP Gen (hIAPP, RIPHAT 
Ratten) exprimieren. NI-203.26C11 verbesserte die Glukose Toleranz sowie die β-Zell 
Funktion, erhöhte die Insulin Sekretion, reduzierte die Nüchternglukose und 
normalisierte die Gewichtszunahme bei den RIPHAT Ratten im Vergleich zu 
Kontrolltieren. In einer Dosis-Wirkungs-Studie wurden die drei getesteten Dosierungen 
(1, 3, 10 mg/kg) als sicher und wirksam eingestuft. Interessanterweise zeigten 1 mg/kg 
und 10 mg/kg eine bessere Wirkung als 3 mg/kg bezüglich der Glukose Toleranz und 
der Erhöhung der Insulin Sekretion. Die tiefere Dosierung normalisierte sogar die 
Gewichtszunahme. Folglich stellt die passive Immunisierung eine vielversprechende 
Strategie in der Behandlung von T2DM dar. 
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2 Summary 
Type 2 diabetes (T2DM) is one of the most important public health challenges in 
humans. One of the hallmarks of T2DM is the deposition of islet amyloid derived from 
islet amyloid polypeptide (IAPP) in pancreatic islets. Amyloidogenesis involves the 
stepwise aggregation of IAPP monomers into oligomers, fibrils and, ultimately, mature 
amyloid deposits. The small toxic IAPP oligomers seem to cause β-cell failure and 
death. None of the available treatments against T2DM counteracts the aggregation of 
IAPP and the subsequent loss of pancreatic β-cells. A human-derived antibody NI-
203.26C11, which targets human IAPP aggregates was identified, cloned and 
characterized in vitro and in vivo. Because rat IAPP is not amyloidogenic, transgenic 
rats with the human IAPP gene (hIAPP, RIPHAT rats) were used. NI-203.26C11 
significantly improved glucose tolerance and β-cell function, increased insulin secretion 
and pancreatic insulin content, reduced fasting glucose and normalized body weight in 
NI-203.26C11-treated RIPHAT rats compared to controls. In a dose-response study, 
three different doses of NI-203.26C11 (1, 3, 10 mg/kg) were found to be safe and 
effective in slowing the progression of T2DM. Interestingly, 1 mg/kg and 10 mg/kg 
were generally more effective than 3 mg/kg in improving glucose tolerance and insulin 
secretion. The lower dose even normalized body weight gain. As conclusion, passive 
immunization targeting IAPP aggregates is a very promising approach to treat T2DM.  
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3 Introduction 
3.1 Epidemiology and risk factors of type 2 diabetes mellitus (T2DM) 
Diabetes mellitus is known to be one of the most relevant public health challenges all 
over the world. The number of people with diabetes mellitus has more than doubled 
over the past three decades [1]. Global estimates showed a prevalence of diabetes in 285 
million people in 2010 [2], 90% of whom had T2DM [3]. Newer studies indicated an 
increased worldwide prevalence of diabetes with 415 million people in 2015 and an 
expected rise to 642 million people by 2040 [4]. 
T2DM is a complex illness and depends on interactions between genetic and epigenetic 
predispositions and risk factors such as obesity, physical inactivity, history of smoking, 
being male and hypertension. Overweight and obesity represent the most important risk 
factors for T2DM with the high majority (80-85%) of diabetes cases arising from 
overweight or obese individuals [5].  
3.2 Pathogenesis of T2DM 
The main features of T2DM are insulin resistance and β-cell failure which results from 
reduced β-cell function and/or β-cell mass and leads to defective insulin secretion. 
Inadequate insulin secretion causes hyperglycemia whose micro- and macrovascular 
consequences are atherosclerosis, retinopathy, nephropathy and neuropathy [6], [7], [8]. 
Mechanisms leading to β-cell failure in T2DM include gluco- and lipotoxicity as well as 
the development of islet amyloid deposits caused by islet amyloid polypeptide (IAPP), 
which is also called amylin. Due to the presence of amyloid deposits in T2DM patients, 
the disease is considered a protein misfolding pathology, and in that sense similar to at 
least 30 other disorders, mostly neurodegenerative disorders such as e.g. Alzheimer’s, 
Parkinson’s and Huntington’s chorea [7], [9], [10].  
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3.2.1 Insulin secretion 
In normally functioning β-cells, insulin secretion occurs in two phases. The first phase 
arises rapidly after blood glucose increases, lasts only a few minutes and releases a 
readily releasable pool (RRP) of insulin secretory granules. The second phase is 
characterized by a slow and sustained release of new insulin granules mobilized from 
the reserve pool (RP) [11]. Different complex pathways control this glucose-stimulated 
insulin secretion. In the “triggered pathway” during the first phase, the uptake of 
glucose into the β-cells induces the release of insulin by the secretory granules via the 
formation of mitochondrial ATP production followed by closure of ATP-sensitive K+- 
channels and by β-cell depolarization [12], [11], [13], [14]. To support the “triggered 
pathway” after glucose uptake, the still poorly understood “metabolic amplifying 
pathway” generates down-stream metabolites that amplify insulin secretion especially in 
the second phase of insulin release [11], [15], [14]. Insulin secretion is activated not 
only by glucose but also by hormones (e.g. the incretins glucagon-like peptide-1 (GLP-
Figure 1: Immunohistochemical analysis of pancreatic islets of a healthy person (a) 
and a person suffering from T2DM (b). Representative fluorescent images of islets 
stained for insulin (red) and ThioS-positive amyloid (green). Healthy person (a) shows a 
normal amount of insulin in the β-cells of pancreatic islet. T2DM person (b) shows a 
decreased amount of insulin with a large amount of amyloid deposits. Scale bar: 50 µm 
(Images from Neurimmune AG, Schlieren). 
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1) and glucose-dependent insulinotropic polypeptide (GIP)) and neurotransmitters such
as acetylcholine in so-called “neurohormonal pathways” [11].  
3.2.2 Insulin action 
Insulin binds to the insulin receptor on the surface of many tissues and acts as anabolic 
hormone. It is necessary for the development and growth of tissues and the regulation of 
glucose-homeostasis by glucose-uptake in muscle and adipose tissue and a decreased 
glucose release by the liver [13], [16]. Insulin action is controlled by various 
mechanisms, amongst others by circulating hormones (e.g. glucagon), cytokines, non-
esterified (free) fatty acids (NEFA) and glycerol released by adipose tissue, especially 
by large adipocytes in visceral or deep subcutaneous fat depots [12]. 
3.2.3 Insulin resistance 
As often seen in obese individuals, an enhanced release of NEFA and inflammatory 
cytokines like tumor necrosis factor-α (TNFα) and interleukin-6 (IL-6) affects the 
insulin-signaling cascade and leads to insulin resistance with impaired or failed 
activation of the insulin receptor of peripheral tissues [12], [13]. The ability for glucose-
uptake in muscle and adipose tissue is reduced whereas the liver proceeds with 
gluconeogenesis. This condition results in hyperglycemia [17].  
3.2.4 β-cell dysfunction in obesity and T2DM 
In the presence of insulin resistance, insulin secretion is enhanced to sustain normal 
blood glucose levels which may lead to an increase in β-cell mass. While this 
compensatory mechanism is sufficient to maintain the homeostasis of glucose levels in 
many obese individuals, the β-cell capacity may be exhausted in particular in people 
who are genetically at risk of T2DM with the consequent progressive increase in 
circulating levels of glucose [6].  
The higher oxidative metabolism of glucose induced by hyperglycemic states results in 
an increased production of reactive oxygen species (ROS), leading to endoplasmic 
reticulum (ER) stress and mitochondrial dysfunction, and ultimately to β-cell apoptosis; 
this sequence of events is s also known as gluco-toxicity [9].  
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In obese individuals, dyslipidemia with enhanced NEFA and disturbed lipoprotein 
levels can occur [9]. Long-term exposure to high NEFA concentrations also induces 
oxidative stress in β-cells and suppresses insulin secretion (lipo-toxicity) [14]. The 
concentrations of pro-apoptotic low density-lipoproteins (LDL) and very low density-
lipoproteins (VLDL) are increased and contribute to progressive β-cell failure, while 
high density-lipoproteins (HDL), having a protective effect by inhibiting β-cell 
apoptosis, are decreased [9]. 
In the presence of hyperglycemia, mitochondrial β-oxidation of fatty acids is impaired 
and the following accumulation and esterification of the remaining fatty acids leads to 
harmful high amounts of long chain acyl-CoA. Although the exact mechanism of this 
so-called glucose induced lipo-toxicity or gluco-lipo-toxicity is not completely 
understood, increased amounts of long chain acyl-CoA during hyperglycemia lead to 
aggravated β-cell function and decreased insulin secretion [9], [18]. 
3.3 Islet amyloid polypeptide (IAPP) or amylin 
IAPP is stored as 89-amino acid (aa) preproIAPP together with insulin in the secretory 
granules of the β-cells. IAPP is co-secreted with insulin in a ratio of ca. 1:100 
(IAPP:Insulin). In a first step, a 22-aa signal sequence is cleaved off in the endoplasmic 
reticulum. The remaining 67-aa precursor proIAPP undergoes processing by the two 
endoproteases, i.e.  prohormone convertase 2 (PC2) and prohormone convertase 1/3 
(PC1/3) and the carboxypeptidase E (CPE) to cleave off two flanking peptides at the C- 
and N- terminal ends in the trans Golgi network or secretory granules, respectively. 
Insulin is cleaved from proinsulin to the mature insulin by the same enzymes. A 
disulfide bond between cysteine residues 2 and 7 and a C-terminal amide (Tyr37) are 
constructed via posttranslational modification to yield the biologically active 37-aa 
peptide IAPP, which is then co-secreted with insulin [19] ,[20], [21], [22].  
The IAPP amino acid sequence is closely related to calcitonin-gene related peptide 
(CGRP), calcitonin, adrenomedullin and adrenomedullin 2 [23], [24]. IAPP is a 
satiating hormone which decreases food intake, inhibits gastric emptying and also the 
postprandial glucagon release to lower blood glucose levels [25], [26], [27]. IAPP also 
acts as an adiposity signal and increases energy expenditure [27], [28]. IAPP's effects 
occur via different amylin receptors, belonging to a large superfamily of cell surface G 
protein-coupled receptors and being closely related to calcitonin receptors. These 
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receptors contain one of three different RAMPs (receptor activity modifying protein), 
and with different slice variants of the calcitonin core receptor, several variable amylin 
receptor subtypes are formed [24], [29], [30]. Hormonal IAPP acts via the area postrema 
(AP) to induce the above mentioned effects [27].  
3.3.1 Differences between species 
Non-human primates and cats are the only non-human species showing pancreatic islet 
amyloid deposits and being prone to developing a form of T2DM which mimics the 
human features. The primary structure of IAPP is highly conserved among species, 
besides differences in the amino acid residues 20-29 which do not seem to be critical for 
the hormonal action of IAPP [31], [32], [33], [34]. IAPP from primates and cats easily 
aggregates by forming β-sheet structures. In contrast, in mice and rats, three proline 
residues within the region 20-29 were shown to act as β-sheet breakers [35] and 
therefore, rodents, even though they synthesize and secrete IAPP, do not exhibit islet 
amyloid or suffer from a T2DM- like syndrome [36], [37], [38].  
Figure 2: Primary structure (aa1-37) of IAPP in several species: The amyloidogenic 
region contains aa- residues 20-29 (blue). Due to three proline residues (orange) in this 
region of IAPP in rats and mice, these species are not prone to developing islet amyloid 
and a T2DM-like syndrome (modified by E. Jaikaran et al., 2001). 
3.4 Pancreatic islet amyloid 
Pancreatic islet amyloid was first described in 1901 as homogenous material that stains 
with eosin and was originally called hyaline material [39]. IAPP-derived amyloid 
deposits can be found in over 90% of all human patients suffering from T2DM, but also 
in some mostly elderly people without diabetes [37]. These findings in healthy 
individuals gave rise to the question whether and how islet amyloid is related to the 
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pathogenesis of T2DM. There is strong evidence that the formation of toxic oligomers 
derived from amyloidogenic IAPP causes β-cell dysfunction and apoptosis leading to 
impaired insulin secretion, and plays an important role in the pathogenesis of T2DM 
[7], [10]. 
Mature amyloid deposits, visible by light microscopy, may impair the cell-to-cell 
contact through connexin-36 gap junction channels by occupying the space between β-
cells and thus lead to reduced transfer of insulin and nutrients between the cells [21], 
[37]. However, the main cytotoxic species of IAPP are intracellularly formed small 
oligomers causing membrane disruption and leakage. These small oligomers are only 
visibly by electron microscopy. Because rodent IAPP is not amyloidogenic, mice and 
rats transgenic for human IAPP (hIAPP) have been generated to study underlying 
mechanisms. It has e.g. been observed that homozygous hIAPP transgenic mice, which 
develop diabetes quite early in life (10 weeks of age) due to high β-cell loss, did not 
show any extracellular islet deposits at this stage. Hence, the “amyloid hypothesis” that 
suggests that mature amyloid deposits cause cytotoxicity, had to be given up and the 
pathophysiology is probably explained better by the so-called “toxic oligomer 
hypothesis”. Nonetheless, since large fibrils achieve a stationary phase with a balance 
between assembly and dismantling of oligomers, it is suggested that large amyloid 
deposits may represent a reserve for small toxic oligomers [6], [10], [40], [41]. 
However, the mechanisms causing β-cell death are still not fully understood [42]. 
Figure 3: Schematic image of formation of IAPP oligomers and amyloid fibrils 
originating from IAPP monomers. Oligomers can lead to toxic oligomers (modified by 
L. Haataja et al., 2008). 
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3.4.1 Islet amyloid formation 
Besides the harmful effects of high glucose and disturbed lipid levels (see 3.2.4), one of 
the main causes of β-cell exhaustion is the enhanced rate of apoptosis in β-cells due to 
increased endoplasmic reticulum (ER) stress induced by high levels of misfolded 
hIAPP, finally resulting in the formation of visible islet amyloid deposits [6], [43].  
Important factors leading to amyloid formation are environmental changes, abnormal 
pro-hormone processing and advanced glycation of hIAPP end products and insulin. 
Since insulin and hIAPP are co-secreted, an abnormal increase of local intracellular 
hIAPP is associated to the increase in insulin secretion caused by insulin resistance [37], 
[44]. It is known that insulin and a low pH in the secretory granules have a stabilizing 
effect on hIAPP, preventing the fibril formation [10]. Proinsulin, which is often 
increased in the secretory granules of the β-cells during the process of T2DM, has not 
such a preventing effect, leading to a higher rate of intracellular hIAPP oligomer 
formation. Additionally, mutations in the hIAPP gene, such as the S20G mutation 
(heterozygous substitution of hIAPP at position 20 of a serine residue for a glycine), 
may lead to a more amyloidogenic version of hIAPP and, therefore, cause enhanced 
amyloid formation [37], [44], [45]. 
A predicted model of the secondary structure of hIAPP monomers consists of three 
antiparallel β-sheets composed of three amyloidogenic regions, built up by a first β-turn 
at asparagine31 and a second one at serine20, leading to an intramolecular β-sheet 
stabilized through several hydrogen bonds [46]. Later, it was assumed that the 
monomers form two β-strands, connected by a loop containing the amyloidogenic 
region 20-29, linked by several hydrogen bonds [42]. The aggregation of misfolded 
monomers leads to the formation of oligomers with a tertiary structure of crossed β-
sheets [21], [38]. Gurlo and coworkers demonstrated that toxic oligomers are formed in 
the secretory pathway and escape into the cytosol by causing direct membrane damage 
[47]. While it is still not clear, if toxic oligomers and amyloid fibrils result from the 
same aggregation-pathway, it seems that both of them have an intracellular origin [42].  
“Nucleation-dependent fibrillation” represents the prevailing model of amyloid 
formation not only in T2DM but also in other protein-misfolding diseases such as e.g. 
Alzheimer’s, Parkinson’s and Huntington’s chorea. The “nucleation-dependent 
fibrillation” takes place in three successive phases: the first or so-called lag phase with 
nucleus formation out of mono- and oligomers acting as template, but no fibrillar 
growing, the second exponential growth phase with accelerated fibrillation due to 
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accelerated adhesion of monomers and finally, the stationary phase with no additional 
fibrillar growth based on a balance between build-up and decomposition of the amyloid 
fibrils [10], [48]. 
IAPP amyloid deposits could also be found in kidneys, the temporal-lobe gray matter of 
the brain and in blood vessels and IAPP oligomers in the heart of T2DM patients [10]. 
Pancreatic amyloid deposits in humans, monkeys and cats start as small fibrils close to 
islet capillaries in single islets, spread to almost all islets (increasing islet prevalence) 
and finally lead to an increased amount of amyloid deposits per islet [37]. In 2011, 
Jurgens and coworkers demonstrated that in T2DM, the β-cell mass decrease due to 
apoptosis is strongly related to increasing amounts of islet amyloid [7].  
3.4.2 β-cell dysfunction due to islet amyloid 
3.4.2.1 Apoptosis 
In T2DM, toxic intracellular small oligomers induce β-cell apoptosis through the 
intrinsic pathway mostly by initiating ER stress, mitochondrial dysfunction, oxygen 
stress and inflammation, while the extrinsic pathway is activated by extracellular 
receptor-binding due to inflammation or direct cell membrane disruption [6], [38], [49]. 
It seems that hIAPP fibrils, rather than toxic oligomers, cause direct membrane damage 
[22]. 
3.4.2.2 Mechanisms activating the intrinsic pathway 
The normal function of the endoplasmic reticulum (ER) is to synthetize and fold 
secretory proteins and to transfer them into the Golgi and secretory vesicles. Under 
normal conditions, the unfolded protein response (UPR), high Ca2+ concentrations and 
also an oxidative environment in the ER prevent misfolding of secretory proteins. The 
UPR ensures the ER function by activating several mechanisms leading to decreased 
translation of main ER client proteins. Furthermore, the UPR provides increased 
amounts of chaperones, necessary for the prevention of misfolding, and other proteins 
responsible for the clearance of un- and misfolded ER proteins. In T2DM, insulin 
resistance leads to an increased synthesis and secretion of insulin and IAPP, causing an 
overload in the ER. This leads to a highly increased burden for the UPR and any 
additional charges can easily lead to an imbalance of this protective system; finally, ER-
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stress induced apoptosis may occur. Misfolded hIAPP oligomers may then lead to 
membrane disruption by causing nonselective ion channel activity and Ca2+ leakage of 
the ER, followed by mitochondrial membrane leakage of cytochrome c and activation of 
several caspases, protein kinases involved in the initiation of apoptosis. Additionally, 
Ca2+ leakage through toxic hIAPP oligomers activates ER associated calpain with the 
ability to induce caspase-independent apoptosis [6], [47]. 
Besides acting as nonselective ion channels, toxic hIAPP oligomers can directly disrupt 
the membranes of the secretory pathway in β-cells. Subsequently, toxic hIAPP 
oligomers in the cytosol cause direct membrane-damage of cytosolic cell organelles 
such as mitochondria, finally leading to mitochondrial dysfunction induced apoptosis 
[47]. Additionally, hIAPP oligomers can lead to instable mitochondrial membrane 
potential, causing high amounts of harmful reactive oxygen species (ROS) [10].  
Especially in long living cells such as β-cells, there are three characterized mechanisms 
to remove misfolded or otherwise damaged proteins: the ubiquitin proteasome system 
(UPS), autophagy and aggresome formation. The UPS operates by marking abnormal 
proteins with ubiquitin chains. This leads to entering the proteolytic proteasome after 
removing ubiquitin chains by several enzymes. In β-cells, the most common 
deubiquinating enzyme is the ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1). It 
seems that enhanced amounts of hIAPP decrease the expression of UCH-L1 in β-cells 
by unknown mechanisms, causing deterioration in the UPS, leading to accumulation of 
ubiquinated proteins and cytotoxicity.  
Autophagosomes are membrane-bound vesicles, enclosing damaged proteins or other 
cell structures, conveying them to the lysosome where proteolysis takes place [10]. It is 
suggested that hIAPP oligomers impair lysosomal proteolysis, leading to high 
concentrations of hIAPP aggregates and cell death. The so-called aggresome is the 
designation of cytosolic inclusions at the microtubule organizing center, enclosing 
escaped misfolded proteins to ensure their degradation by the UPS or autophagy. 
However, if the function of the UPS and autophagosome system is impaired, 
aggresomes cannot be abolished, leading to β-cell apoptosis through different above 
described mechanisms [10]. 
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3.4.2.3 Mechanisms activating the extrinsic pathway 
Amyloid deposits are known to cause inflammation in affected islets [38]. Immune cell 
infiltration seems to take place in all patients suffering from T2DM [8]. Phagocytosed 
aggregates may lead to inflammasome-activation in macrophages, a molecular multi-
protein complex causing the release of inflammatory cytokines such as IL-1β and IL6 
[10], [38]. Increased secretion of these pro-inflammatory cytokines seems to activate the 
extrinsic pathway by ligand binding [50]. Additionally, direct extracellular binding of 
toxic hIAPP to the "death receptor" FAS also activates the extrinsic pathway, causing 
apoptosis by the activation of caspase 3 [38].  
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Figure 4: Intrinsic and extrinsic pathways of apoptosis in β-cells caused by toxic 
oligomers or amyloid fibrils. ER= endoplasmic reticulum, UCH-L1= ubiquitin 
carboxyl-terminal hydrolase L1, IL-1β= Interleukin-1β, IL-6= Interleukin-6. 
To finally understand the complicated nature of islet amyloid and its effect on β-cell 
survival, it is important to appreciate that all the above described pathological 
mechanisms, leading to this complex disease pattern, take place in parallel and interact 
with each other in various ways. Whether islet amyloid is a cause of T2DM or a 
consequence, leading to further loss of β-cells and hence contributing to the severity of 
the disease, still needs further investigation.  
3.5 Rodent models of T2DM 
Diabetes not only negatively influences the quality of life of affected people, but also 
causes immense health care costs. In 2014, it has been estimated that the worldwide cost 
of T2DM was at least 612 billion USD, and Europe, North America and the Caribbean 
Region caused about 69% of the above mentioned costs [51]. The fact that T2DM is 
increasingly seen in young adults [52], with a particularly high risk of cardiovascular 
diseases [53], leads to the obvious conclusion, that there is an urgent need of strategies 
to prevent the development and to improve the treatment of T2DM [54], [55]. T2DM in 
humans is a slowly progressive disease, characterized by defective insulin secretion due 
to β-cell dysfunction or loss of β-cell mass, insulin resistance and deposition of islet 
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amyloid derived from hIAPP. It usually takes years for the full clinical picture including 
micro- and macrovascular complications to develop [6], [54], [55]. Therefore, the use of 
animal models which show a much faster development of diabetes, its symptoms and 
complications represents a logical and efficient strategy in research. So far, there is no 
rodent model comprehensive of all characteristics of T2DM, including the same 
pathogenesis, symptoms and complications. However, there are several rodent models 
mimicking at least some aspects of T2DM [55], [56], [57]. An example of a rodent 
model that mimics the pathophysiology of obesity and insulin resistance, leading to 
elevated blood glucose levels, represents the diet induced obesity (DIO) mouse, a 
C57BL/6 mouse developing a diabetic syndrome when fed with high fat diet [58], [59].  
3.5.1 hIAPP transgenic models 
Since rodent IAPP is not amyloidogenic, the development of transgenic mice and rats 
expressing the hIAPP was necessary to study this particular aspect of the T2DM 
pathophysiology [59]. These models helped to study the pathophysiology of islet 
amyloid and the effectiveness of anti-amyloid treatment in rodents. Due to the human 
transgene in these animals, the study of amyloid deposits in T2DM became possible 
[54]. Spontaneously developing diabetes was observed in transgenic mice homozygous 
for hIAPP (h-IAPP(homozygous):FVB/N) [60], while hemizygous transgenic hIAPP 
mice (h-IAPP(hemizygous):C57BL76J) did not become diabetic [61]. Actually, in 
heterozygous mice, several strategies are needed to increase the burden of the transgene 
to initiate a diabetic phenotype [54]. The administration of growth hormone or 
dexamethasone (h-IAPP(hemizygous):FVB/N) [62], high fat feeding (h-
IAPP(hemizygous):C57/6xDBA) [63],  and crossbreeding onto an obese background 
such as Avy/Agouti (h-IAPP(hemizygous):Avy/A) or Lepob/ob (h-IAPP(hemizygous): 
ob/+) were described to provoke a diabetic phenotype with impaired glucose tolerance, 
amyloid deposits and hyperglycemia [64], [65].  
Similar to the mouse models, the HIP rat (hIAPP) or RIPHAT rat (rat insulin II 
promoter human IAPP transgenic rat) is a transgenic rat model expressing hIAPP, 
which was generated by Butler and colleagues in 2004 to overcome the limitations often 
seen in mice [66]. A transgene construct with a cDNA sequence coding for the human 
IAPP and the rat insulin II promoter was generated and microinjected to fertilized 
Sprague Dawley rat eggs. The hemizygous line, exhibiting a midlife onset of diabetes 
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due to hIAPP expression in β-cells and representing the usual onset of the disease in 
humans, was identified. Because males are more prone to diabetes than females, only 
male rats of this line were selected (HIP or RIPHAT rats, see table 1 for characteristics). 
Homozygous rats developed an early onset of diabetes without visible amyloid deposits 
[66]. 
Table 1: Comparison between Sprague Dawley rats and hemizygous RIPHAT rats 
(modified by Butler et al., 2004). 
Criteria Wild type control rat 
(Sprague Dawley: SD) 
RIPHAT rat 
(CD:SD-Tg(ins2-IAPP)Soel ) 
Bodyweight (BW) Normal BW of Sprague Dawley  
rats (Charles River Laboratories) 
20% lower than wild type rats after 5 
months of age 
β- cell mass Increased by 60% from 5 to 18 
months of age  
Decreased by 90 % from 5 to 18 
months of age, with a 60% decrease 
at the onset of diabetes 
β-cell replication 
and apoptosis 
Constant rate of replication and 
apoptosis from 5 to 18 months of 
age 
Increased rate of replication and 
apoptosis from 5 to 18 months of 
age, replication not able to 
compensate for increased apoptosis, 
leading to loss of β- cell mass 
Islet amyloid No islet amyloid at any stage Islet amyloid present at 2 months of 
age, increasing and reaching a 
plateau at 10 months of age 
Phenotype No impaired fasting glucose and 
no onset of diabetes at any stage 
Impaired fasting glucose at 5 months 
of age, onset of diabetes between 5 
and 10 months of age 
3.6 Anti-amyloid treatment 
Management of T2DM usually involves lifestyle changes such as diet and exercise to 
lose body weight, leading to improved tissue insulin sensitivity. It also includes 
treatment with a large number of anti-diabetic drugs to lower the high blood glucose 
levels and, if necessary, antihypertensive and anti-platelet medications against diabetes 
associated complications [12], [67]. No approved drug, however, is available to inhibit 
IAPP aggregation and the subconsequent impairment in β-cell function [10]. 
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3.6.1 Aromatic organic compounds 
In 1994, Congo Red was shown to inhibit hIAPP amyloid fibril toxicity but did not 
prevent the formation of hIAPP fibrils in vitro [68]. However, Aitken and coworkers 
published contradictory results in 2003, demonstrating the ability of Congo Red to not 
only inhibit the hIAPP toxicity and fibril formation but also to reduce hIAPP amyloid 
content in vitro [69]. Rifampicin and its analogues, p-benzoquinone and hydroquinone, 
were shown to inhibit the toxicity of aggregated hIAPP peptides without preventing the 
hIAPP fibril formation in vitro. This inhibitory effect on hIAPP aggregate toxicity is 
caused by the binding to hIAPP fibrils and by preventing their contact to the cell-
surfaces [70]. On the other hand, Meier and coworkers demonstrated in 2006 that 
rifampicin does prevent the formation of mature hIAPP fibrils but not the formation of 
toxic hIAPP oligomers in vitro [71]. Therefore, the administration of rifampicin did not 
protect intracellularly hIAPP expressing RIN cells, nor β-cells of isolated pancreatic rat 
islets of RIPHAT rats from hIAPP toxicity caused by toxic hIAPP oligomers. In fact, 
the addition of rifampicin to the above mentioned in vitro and ex vivo cells rather 
increased the cell-toxicity of toxic hIAPP oligomers. A possible explanation might be 
that the inhibition of fibril formation by rifampicin prevented oligomers to be 
transferred into potentially less toxic large fibrils and thus lead to a higher amount of 
toxic hIAPP oligomers. Hence, the administration of rifampicin or related structures 
appears to be unsuitable in preventing T2DM [71].  
3.6.2 Unmodified short peptides 
Short peptides derived from hIAPP amyloidogenic regions were designed and tested in 
vitro for their effects on the fibrillogenesis of the full-length peptide (see also figure 2). 
Peptides containing the hIAPP sequences 20-25 and 24-29 from the amyloidogenic 
region 20-29 (SNNFGAILSS) of hIAPP were shown to inhibit β-sheet formation and 
amyloid aggregation, while the peptide 22-27 (NFGAIL) rather increased the ability of 
hIAPP to form insoluble fibrils [72], [73]. The hIAPP residues 13-18 (ANFLVH) from 
a second fibrillogenic hIAPP region [74] were shown to be potent amyloid aggregation 
inhibitors in vitro [75]. Recently, the anti-amyloid efficacy of the residues 13-18 
(ANFLVH) of hIAPP have been tested in vivo by using a hIAPP transgenic mouse 
model, leading to improved glucose tolerance by reduced islet cell apoptosis and 
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preservation of β-cell area in transgenic mice treated with ANFLVH compared to 
transgenic control mice [76].  
 
3.6.3 Modified short peptides 
Another peptide-based strategy was rested upon the use of structure-based non-
amyloidogenic derivatives of the hIAPP peptide. Double N-methylation of the hIAPP 
fibrillogenic region 22-27 [77] increased the binding-affinity of derivatives to full-
length hIAPP, prevented the aggregation of fibrils into amyloid and decreased β-cell 
apoptosis [78]. The N-methylated derivative was used to generate a full-length 
molecular mimic of hIAPP called IAPP-GI [79] that was shown to inhibit the amyloid 
aggregation and cytotoxicity of unmodified hIAPP in vitro [80]. Another group 
demonstrated that a point-mutation of isoleucine at position 26 to a proline residue 
transformed the natural hIAPP sequence into a potent amyloid aggregation inhibitor 
[81]. 
An all-D-amino-acid substituent of hIAPP segment 22-27 (NFGAIL) revealed to be 
another successful peptide-based approach to inhibit amyloid formation [82]. Whereas 
most of these approaches targeted amyloid fibrils [77], [78], [80], [81], other studies 
demonstrated that two pentapeptides derived from the incorporation of non-natural 
amino acid (α,β-dehydrophenylalanin) into the amyloidogenic core region of hIAPP22-
27 were capable of binding monomeric forms of hIAPP and to decrease the formation of 
hIAPP oligomers [83]. Because of the increasing evidence for oligomers to be more 
toxic than mature fibrils [6], [84], inhibition of hIAPP aggregation at the earliest stage 
before oligomers are formed, is thought to be the most promising strategy [83].  
 
3.6.4 Flavonoids and other strategies 
Flavonoids such as flavonol (-)-epigallocatechin 3-gallate (EGCG) [85], [86] and the 
hydroxyflavone Morin hydrate [87] have been shown to not only inhibit amyloid 
fibrillation by binding to hIAPP monomers, intermediates and fibrils, but even to 
disaggregate hIAPP amyloid fibrils in vitro.  
Recently, several additional strategies to prevent hIAPP amyloid formation have been 
under investigation. One in vitro approach took advantage from the inhibitory effect of 
Copper ions [Cu(II)] on hIAPP aggregation [88]. Another research group has examined 
the application of a polymeric nanoparticle, the generation-3 OH-terminated poly 
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(amidoamine) dendrimer, to bind to the amyloidogenic hIAPP residues 22-29 and 
therefore, to inhibit hIAPP amyloid aggregation [89]. Last, the heat shock protein 
Hsp72 (HSPA1A) showed inhibitory effects against hIAPP aggregation and cell-
toxicity in vitro. Additionally, Hsp72 enhanced h-proIAPP solubility in vivo in a novel 
transgenic h-proIAPP C. elegans model [90]. 
3.6.5 Immunotherapy 
Similar to T2DM, Alzheimer's disease (AD) is also a member of the so-called protein-
misfolding or amyloid diseases that are due to aggregating proteins leading to oligomers 
and amyloid fibrils with harmful effects such as oxidative stress and inflammation, 
finally causing loss of neurons or β-cells, respectively [10], [91]. While islet amyloid in 
T2DM is built up by IAPP, the aggregating protein in AD is amyloid-β protein (Aβ), 
leading to extracellular neuritic plaques [92]. The most widely developed and promising 
approach to target Aβ in AD is the use of passive immunotherapy. Several phase III 
clinical trials for antibodies, such as Crenezumab [92] or Aducanumab from 
Neurimmune Holding AG (Schlieren, Switzerland), are still ongoing [93] and some 
phase III clinical trials, e.g. for the antibody Solanezumab, are already conducted [94]. 
Considering these approaches to treat AD, it seems obvious that amyloid-directed 
immunotherapy may also be an attractive approach to target islet amyloid deposits in 
T2DM.  
Several research groups investigated the use of an immunotherapeutic approach to treat 
T2DM. Bram and coworkers detected specific antibodies from human diabetic donors 
that were able to bind toxic oligomers and to decrease their cytotoxicity in vitro [84]. 
Their work not only confirmed the toxic oligomer hypothesis (see 3.4, [6]) by 
identifying IAPP soluble oligomers to be the most cytotoxic forms during the process of 
T2DM, but also supported the idea of using antibodies to target IAPP for the treatment 
of T2DM. To design anti-amyloid domain antibodies specific for IAPP in T2DM and 
Aβ in AD, Lee and coworkers used a motif-grafting approach in vitro by grafting 
amyloidogenic peptide segments of IAPP and Aβ into complementarity-determining 
regions of single domain antibodies. However, these specific anti-IAPP domain 
antibodies have not yet been tested in vivo [95].  
Krishnamurthy and coworkers used hemizygous hIAPP transgenic mice on a mixed 
DBA/2-C57Bl-6 background to investigate the feasibility of an active 
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immunotherapeutic approach to target islet amyloid aggregates by injecting full-length 
hIAPP or a hIAPP derivative containing the amino acids 7-19 (IAPP7-19) [96]. The 
modest antibody response of monthly vaccination between 2 and 14 months of age 
against full-length hIAPP in the IAPP7-19 derivative study seemed to be sufficient to 
bind toxic soluble oligomers. The very high anti full-length antibody response generated 
in the full-length hIAPP study appeared to lead to a negative effect on glucose 
regulation. Since it may be quite difficult to control a specific level of antibody response 
in different individuals, it seems that passive immunization with IAPP targeting 
antibodies might be preferable to active immunization strategies [96].  
3.7 Preliminary data 
Preliminary studies were conducted to test the therapeutic efficacy of a passive 
immunization with high affinity human-derived antibodies targeting pathologically 
misfolded forms of hIAPP in transgenic rodent models of T2DM expressing hIAPP. 
Because the toxic effect of amyloid fibrils may be due to small oligomers within the 
cells, before extracellular amyloid is visible, lead antibody candidates that target 
misfolded hIAPP have been identified, cloned and reproduced. 
Identified antibodies were validated in vitro for their affinity and selectivity to 
pathological hIAPP oligomers and fibrils in pancreatic tissue of human diabetic 
subjects. The NI-203.26C11 antibody showed very high selectivity for pathological 
hIAPP and no binding to the native conformation of physiological monomeric hIAPP in 
healthy subjects. Thus, NI-203.26C11 was selected for validation in vivo in transgenic 
models expressing hIAPP. All data were generated in collaboration with Neurimmune 
AG, Schlieren. 
3.7.1 Mouse study 
In FVB/N-Tg(Ins2-IAPP)RHFSoel/J mice, the chronic administration of the antibody 
NI-203.26C11 was well tolerated and safe. However, the phenotype of the "RIPHAT" 
homozygous mice was very severe and diabetes progressed rapidly. Spontaneous death 
was observed during the experimental time in both NI-203.26C11- or PBS-treated 
homozygous groups. The immunotherapy did not improve glucose control, glucose 
tolerance and insulin secretion nor was it effective in slowing the progression of 
diabetes in this severely diabetic mouse model. We believe that this mouse model 
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presumably progressed too rapidly into a pathological phenotype which does not reflect 
the pathophysiology of the disease in humans. The normal progression of T2DM in 
humans is a slow chronic process that takes place over years. Hence, it is difficult to 
predict the effect that a chronic anti-amyloid antibody administration would have in 
humans [97].  
3.7.2 Rat study I (HIP1) 
Male hemizygous RIPHAT rats (CD:SD-Tg(ins2-IAPP)Soel) [66] and male Sprague 
Dawley wild type (WT) rats were used. A chimeric version of the antibody (NI-
203.26C11-r) containing human variable domains and rat IgG2b constant regions, was 
generated to reduce neutralizing effects against human NI-203.26C11 in rats. Rats 
received weekly i.p. injections of the NI-203.26C11-r antibody (3 mg/kg) or PBS 
starting at 12 weeks of age for 18 weeks. Oral glucose tolerance tests (oGTT) were 
conducted one week before, as well as 8 and 16 weeks after the start of the treatment. 
Additionally, fasting blood glucose values were measured 4 and 12 weeks after chronic 
treatment. After 18 weeks of treatment, all rats were sacrificed, insulin and hIAPP levels 
were measured and histological and immunohistochemical analyses of the pancreas 
were performed to evaluate islet area, insulin immunoreactive pancreatic β-cell area and 
islet amyloid. Glucose tolerance was significantly improved after 8 and 16 weeks by NI-
203.26C11-r compared to PBS treatment in RIPHAT rats. Insulin levels tended to be 
higher and hIAPP levels were significantly higher in RIPHAT rats treated with NI-
203.26C11-r in comparison with RIPHAT rats that received PBS. There were no effects 
on body weight (BW), fasting blood glucose, mean islet and insulin immunoreactive 
area in the first conducted rat study [98].  
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Figure 5: Rat study I (Data from M. Osto, 2014): Plasma hIAPP (a) and plasma 
insulin levels (b) in RIPHAT (tg) rats treated with NI-203.26C11-r antibody or PBS 
after 18 weeks of treatment. RIPHAT rats that received NI-203.26C11-r treatment 
showed significantly higher plasma hIAPP levels (a) and a trend for having higher 
plasma insulin levels (b). 
3.7.3 Rat study II (HIP2) 
In the second rat study, RIPHAT rats (CD:SD-Tg(ins2-IAPP)Soel) [66] and wild type 
(WT) Sprague Dawley rats were treated for 28 weeks with the antibody NI-203.26C11-r 
(3 mg/kg), an isotype control IgG or PBS. Again, glucose tolerance was significantly 
improved after 17 weeks of treatment in RIPHAT rats that received NI-203.26C11-r 
compared to PBS or isotype controls. A hyperglycemic clamp performed after 20 weeks 
of chronic treatment showed a significant increase in insulin secretion in RIPHAT rats 
treated with NI-203.26C11-r compared to RIPHAT rats treated with control IgG. 
Fasting blood glucose was significantly reduced in NI-203.26C11-r treated RIPHAT 
rats compared to transgenic control rats and NI-203.26C11-r normalized fasting glucose 
to the levels seen in wild type rats. Control RIPHAT rats started to lose BW after 20 
weeks of treatment probably due to progressive glucosuria while RIPHAT rats treated 
with NI-203.26C11-r continued to gain weight. The difference in BW compared to 
control RIPHAT rats was significant after 24 weeks of treatment. Additionally, in the 
histological examination of pancreatic tissue of all rats, β-cell content was significantly 
reduced in RIPHAT control rats compared to treated RIPHAT rats. Overall, the 
treatment with NI-203.26C11-r antibody improved glucose tolerance, reduced 
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hyperglycemia, increased plasma insulin levels, preserved β-cell content and normalized 
BW gain in transgenic hIAPP rats [99].  
a) b) 
Figure 6: Rat study II (Data from M.Osto, 2015): Hyperglycemic clamp performed 
after 20 weeks of treatment in RIPHAT (tg) rats treated with NI-203.26C11-r antibody 
or IgG control. All rats received a glucose bolus (375 mg/kg) followed by 50% glucose 
infusion (a) to clamp arterial glucose at 270mg/dl (0-60 min). (b) Plasma insulin levels 
(% baseline) in RIPHAT rats treated with NI-203.26C11-r were significantly higher 
than in RIPHAT rats that received IgG control, indicating an increased β-cell function 
in NI-203.26C11-r treated rats. 
Figure 7: Representative fluorescent images of pancreatic islets in RIPHAT (tg) rats 
of the HIP2 study after 20 weeks of treatment. RIPHAT rat treated with vehicle control 
(left) showed reduced insulin staining (red) but increased ThioS-positive amyloid
staining (green) compared to NI-203.26C11-r treated RIPHAT rat (right). 
Scale bar: 50 µm. (Images from Neurimmune AG, Schlieren). 
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4 Aim of the study 
The principal aim of the current study was to determine the most effective dose of NI-
203.26C11-r antibody in hIAPP transgenic rats. In order to achieve this aim, three 
different doses (1, 3 or 10 mg/kg) of the antibody NI-203.26C11-r were administered 
weekly in RIPHAT rats. The efficacy of the passive immunotherapeutic approach in this 
dose-response study was assessed by measuring blood glucose and plasma insulin levels 
during oral glucose tolerance tests before and throughout the treatment period.  
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5 Material and Methods 
5.1 Animals and housing conditions 
In total, 74 hemizygous transgenic male RIPHAT rats (Crl:CD (SD)-Tg (Ins2-IAPP) 
1Pfi; [66]) and 13 wild-type male Sprague-Dawley rats (WT; CR:CD (SD)) were 
included in the study (Charles River Laboratories, Wilmington, MA, USA). Rats were 
kept in a temperature controlled room (21 ± 1°C) on a 12:12 hours light/dark cycle 
(lights off from 2pm to 2am) with ad libitum access to standard chow (Extrudate 3436, 
KLIBA NAFAG, Kaiseraugst, Switzerland) and water. Rats were housed in standard 
cages (Type 2000P, 612x435x216mm, Tecniplast, Buguggiate, Italy), in groups of two 
to three animals per cage. Before starting any treatment, rats (9 weeks old) were handled 
every second day and given an adaptation period of 3 weeks before being randomized 
into treatment groups. The experiments were approved by the Veterinary Office of the 
Canton Zurich, Switzerland (licence nr. 143/2015). 
5.2 Study design 
5.2.1 Injection protocol 
RIPHAT (N=74) and WT (N=13) rats were divided into four treatment groups each: 
Group I received phosphate buffered saline (PBS, 2 ml/kg, Gibco, Auckland, NZ), 
group K, G and H were administered a rat chimeric version of the human anti-hIAPP 
antibody: NI-203.26C11-r at 1, 3 or 10 mg/kg in 2 ml/kg PBS, respectively (see table 2 
for the number of rats per group). 
Intraperitoneal (i.p.) injections were initiated at 12 weeks of age and repeated weekly 
until the end of the experiments at 53 weeks of age. Oral glucose tolerance tests (oGTT) 
were performed at 12, 20, 26, 30, 34, 38, 42, 46 and 51 weeks of age. The first oGTT at 
12 weeks of age was done before the start of any treatment and data collected at this 
time served as a baseline. Fasting glucose and insulin levels were measured during the 
oGTT (see paragraph 5.2.3 for details) and BW was measured weekly to monitor rats’ 
health and to determine the injection volume.  
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Table 2: Total number of rats used in the study, divided into the four treatment groups 
I (control), K (1 mg/kg), G (3 mg/kg) and H (10 mg/kg) of NI-203.26C11-r, 
respectively. 
5.2.2 Human anti-IAPP antibodies 
Antibodies against human IAPP were produced by Neurimmune Holding AG 
(Schlieren, Switzerland). Reactive memory B-cells were isolated from peripheral blood 
of healthy human donors. Conditioned media derived from human memory B-cell 
cultures were screened for antibodies binding to aggregated IAPP protein and absence 
of binding to bovine serum albumin (BSA), using a direct ELISA approach. Only 
cultures of B-cells positive for aggregated IAPP protein but not for BSA were used for 
antibody cloning.  
Selected antibodies were recombinantly produced and further analyzed for class and 
light chain subclass determination. These antibodies were characterized for their 
binding specificities towards aggregated or non-aggregated hIAPP protein by direct 
ELISA on 96-well plates (Costar, Corning, USA) coated with human IAPP solution 
which contained IAPP fibrils or BSA (Sigma-Aldrich, Buchs, Switzerland) diluted to a 
concentration of 10 μg/ml in carbonate ELISA coating buffer (15 mM Na2CO3, 35 mM 
NaHCO3, pH 9.42). After overnight incubation at room temperature, binding efficiency 
of the antibodies was tested by blocking non-specific binding sites for 1 hour at room 
temperature with PBS/0.1% Tween-20 (polysorbate surfactant) containing 2% BSA 
(Sigma-Aldrich, Buchs, Switzerland). 
After being transferred to ELISA plates, B-cell conditioned medium or recombinantly 
produced antibodies were incubated at room temperature for one hour. ELISA plates 
were washed in PBS-Tween 20. Binding was determined using horseradish peroxidase 
(HRP)-conjugated anti-human IgG polyclonal antibodies (Jackson ImmunoResearch, 
Treatment WT rats RIPHAT rats Total 
I (PBS 2 ml/kg) 3 18 21 
K (NI-203.26C11-r 1 mg/kg) 4 19 23 
G (NI-203.26C11-r 3 mg/kg) 3 19 22 
H (NI-203.26C11-r 10 mg/kg) 3 18 21 
Total 13 74 87 
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Newmarket, UK). HRP activity was assessed with standard colorimetric detection using 
a plate reader (Sunrise ELISA reader, Tecan Group Ltd, Männedorf, Switzerland).  
a) b) 
Figure 8: The binding specificity for IAPP of human recombinant antibodies 
assessed by direct ELISA (Data and images from Neurimmune). (a) Electron 
microscopy image of the aggregated IAPP solution (2 mg/ml) used for ELISA plate 
coating. Scale bar = 1 μm. (b) Data expressed as OD values at 450 nm showing a 
specific binding to human IAPP (10 μg/ml) by the recombinant antibody NI-203.26C11, 
but no binding to BSA (10 μg/ml).  
In case B-cell conditioned medium revealed antibodies with selective binding to 
aggregated hIAPP, mRNA of B-cells was prepared and immunoglobulin heavy and light 
chains were cloned with a nested polymerase chain reaction (PCR) approach. This 
approach consists in a modified PCR intended to reduce non-specific binding in 
products due to the amplification of unexpected primer binding sites. Antibodies were 
identified by rescreening on ELISA upon recombinant expression of complete 
antibodies in Chinese Hamster Ovary (CHO) cells and using expression vectors, where 
variable heavy and light chain sequences “in the correct reading frame” were inserted. 
An Ig-heavy-chain expression vector and a kappa or lambda Ig-light-chain expression 
vector were used. The monoclonal antibodies were purified with standard protein A 
column purification and tested again for their binding properties by ELISA.  
The half maximal effective concentration (EC50) was examined using additional direct 
ELISA experiments with varying antibody concentrations. The EC50 values were 
estimated by a non-linear regression using GraphPad Prism software (San Diego, USA). 
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Recombinant human-derived antibody NI-203.26C11 bound with a high affinity to 
human IAPP aggregates with an EC50 of 6 nM.  
By using another direct ELISA experiment, the binding capacity of the antibody NI-
203.26C11 to conformational epitopes was defined. The antibody showed high affinity 
to binding to IAPP fibrils upon coating with the IAPP solution and a loss in affinity to 
nonfibrillar IAPP. These findings lead to the conclusion that the antibody NI-203.26C11 
binds a conformational epitope predominantly exposed on aggregated IAPP species, but 
not to linear epitopes that are present in the physiological monomeric human IAPP 
protein.  
To reduce a rat anti-human antibody response during the treatment, protein engineering 
was used to generate recombinant rat chimeric NI-203.26C11-r antibody, containing 
human variable domains and rat constant regions. Antibodies were purified by affinity 
chromatography to get endotoxin-free antibodies for in vivo validation.  
To assess the affinity and selectivity of NI-203.26C11, fluorescent images for insulin 
and Thioflavin-S (amyloid deposits) of pancreatic tissue in RIPHAT rats and WT rats 
were performed. The presence of amyloid (Thio-S)-positive pancreatic islets was 
confirmed in RIPHAT but not in WT rats. Furthermore, bright field images of the same 
pancreatic islets of RIPHAT and WT rats were stained with NI-203.26C11 and mouse 
anti-IAPP antibody. NI-203.26C11 staining was observed on amyloid (Thio-S)-positive 
islets from RIPHAT rats binding to aggregated hIAPP, but without binding to 
physiological rat IAPP (rIAPP) visualized by the mouse monoclonal anti-IAPP antibody 
on WT rat islets. Interestingly, binding of NI-203.26C11 antibody was also seen on 
Thio-S-negative areas in amyloid (Thio-S)-positive islets from RIPHAT but not WT 
rats. 
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a) 
IAPP       Non-fibrillar IAPP 
b) 
Figure 9: Anti-IAPP antibodies are specific to human IAPP fibrils (Data and images 
from Neurimmune). (a) Electron microscopy pictures of human IAPP (2mg/ml), 
containing fibrils, and nonfibrillar IAPP (500 μg/ml) solutions without any visible 
fibrils, used for ELISA plate coating. Scale bar = 1 μm. (b) Plates were incubated with 
the indicated concentrations of the recombinant human-derived antibody NI-203.26C11, 
and this antibody binds with high affinity to aggregated IAPP fibrils and very low 
affinity to nonfibrillar IAPP without any aggregates. These findings suggest specificity 
of the NI-203.26C11 antibody towards IAPP aggregates. Measurements were made in 
duplicate and background signal on BSA was subtracted. Data are expressed as mean 
OD values at 450 nm. 
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5.2.3 Oral Glucose Tolerance Test (oGTT) 
OGTTs were conducted just before the beginning of the treatment at 12 weeks of age 
and at 8, 14, 18, 22, 26, 30, 34 and 39 weeks after the onset of treatment with NI-
203.26C11-r or PBS. Fasting blood glucose was measured additionally 28, 32 and 41 
weeks after the beginning of the chronic treatment. 
Following a 12 hour fast (from 7pm until 7am), BW was measured and rats received a 
2 g/kg glucose solution (4 ml/kg BW of 50% glucose, B. Braun, Melsungen, Germany) 
by oral gavage. Rats were briefly anesthetized with isoflurane (3-4%, Attane, Piramal 
Enterprises Limited, Mumbai, India) and blood samples (250 μl full blood/500 μl 
EDTA Microtainer K2E tube, Becton Dickinson, Franklin Lakes, USA) were collected 
by sublingual sampling before (0 min) and 15, 30, 60, 120 and 240 minutes after 
glucose load. Blood glucose was assessed using a Breeze2 glucometer and glucose 
stripes (Bayer, Diabetes Care, Zurich, Switzerland). Plasma insulin concentration was 
measured using a rat Insulin ELISA kit from Mercodia (Uppsala, Sweden) following the 
manufacturer’s instructions. 
5.2.4 Plasma and pancreas sampling 
At 53 weeks of age, rats were anesthetized with pentobarbital (60 mg/kg, i.p.) and 
sacrificed by exsanguination via the vena cava caudalis. A minimum of 5 ml full blood 
was collected and plasma was stored at -80°C. The pancreas was collected and fixed 
with 4 % paraformaldehyde (PFA) solution. After 24 hours at 4°C and overnight 
dehydrating in Shandon Citadell 2000 (Thermo Fisher Scientific, Waltham, USA), 
pancreatic tissue was embedded in paraffin blocks (Leica EG1160, using paraplast from 
Leica Biosystems, Wetzlar, Germany), cut into 2.5 μm slides with a microtome (Leica 
RM2255, Leica Biosystems, Wetzlar, Germany), placed on glass slides and stored 
overnight at 60°C.  
5.3 Statistics 
All data were analyzed using GraphPad Prism 5 (San Diego, USA). One-way analysis 
of variances (One-way-ANOVA) with multiple comparisons was used for the analysis 
of fasting glucose, fasting insulin, delta-values and the area under curve (AUC) of 
glucose and insulin levels during the oGTTs. Bonferroni's post-test was used at One-
way ANOVAs including WT and RIPHAT rats, and Dunnet's post-test at One-way 
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ANOVAs including only the RIPHAT rats. Two-way analysis of variances (Two-way-
ANOVA) with multiple comparisons (Bonferroni's post-test) was used to analyze 
glucose and insulin values during the oGTTs. A p- value <0.05 indicated statistical 
significance. All data are presented as mean ± SEM. 
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6 Results 
6.1 Animals 
As described in the literature, the onset of overt diabetes in RIPHAT rats occurs 
between 5 and 10 months of age [66]. In our study, most RIPHAT-PBS control rats 
started to develop a diabetic phenotype, characterized by polyuria and polidipsia 
(PU/PD) and weight loss, at about 36 weeks of age. These clinical signs worsened over 
time but did not result in spontaneous death during the study period (up to 53 weeks of 
age). A similar diabetic phenotype was also observed in approximately half of the rats 
of the antibody-treated RIPHAT groups (RIPHAT-1 mg/kg, RIPHAT-3 mg/kg and 
RIPHAT-10 mg/kg) but the progression of the disease was slower and the diabetic 
phenotype appeared approximately one month later than in control rats (RIPHAT-PBS). 
One rat in the RIPHAT-3 mg/kg group had to be euthanized at the age of 48 weeks, 
because of its excessive weight loss that went beyond the pre-defined ethically 
acceptable level (> 20%).  
Hence, the final number of animals was 18 RIPHAT-PBS rats, 19 RIPHAT-1 mg/kg 
rats, 18 RIPHAT-3 mg/kg rats, 18 RIPHAT-10 mg/kg rats and 13 WT rats receiving 
similar treatment options than the RIPHAT rats (3 WT-PBS rats, 4 WT-1 mg/kg rats, 3 
WT-3 mg/kg rats and 3 WT-10 mg/kg rats). As expected, none of the investigated 
parameters differed significantly between the four different treatment options in WT 
rats and therefore, all four WT groups were taken together into one WT group counting 
13 WT rats.  
Figure 10: Timeline of the entire experimental period with age in weeks as well as 
weeks of treatment in all rats from the 1st until the 9th oGTT and at sacrifice.
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Figure 11: Legend of the symbols, used for all graphs of the study. 
6.2 Body weight 
Body weight (BW) was measured weekly in all rats during the entire experimental 
period. All rats gained weight over the first 9 months of age. WT rats continued to gain 
weight while antibody-treated RIPHAT rats reached a plateau in BW which they 
maintained until the end of the study. On the other hand, RIPHAT-PBS rats started to 
show a weekly decrease in BW (of around 0.5 %) from 37 weeks of age, which resulted 
in a total BW loss of around 8% by the end of the study at 53 weeks of age. There were 
no significant differences in BW between the antibody-treated groups, however, only 
the RIPHAT-1 mg/kg group showed a significantly increased BW compared to 
RIPHAT-PBS rats from 37 weeks of treatment until sacrifice (see figure 12). 
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Figure 12: BW gain of WT and RIPHAT rats over time. The 2nd to the 9th oGTT are 
marked with black grid lines, the sacrifice is marked with a red grid line. From the 
beginning of the study until 24 weeks of treatment, all rats gained weight. RIPHAT(tg)-
PBS rats lost weight from 25th week of treatment until sacrifice at 41 weeks of 
treatment, while antibody-treated RIPHAT rats (RIPHAT(tg)-1 mg/kg, RIPHAT(tg)-3 
mg/kg, RIPHAT(tg)-10 mg/kg) maintained stable BW until the end of the study. See 
legend of the symbols for significant differences. 
6.3 Fasting blood glucose and insulin levels 
6.3.1 Fasting glucose levels 
Fasting blood glucose (FG) levels were measured the first time in 12 week-old rats, i.e. 
just before the weekly antibody treatment was started. At the time of the 1st oGTT (12 
weeks of age), FG was already significantly higher in RIPHAT compared to WT rats 
(see table 3 and figure 13a). 
Significant differences in FG between WT and RIPHAT-PBS rats were seen during the 
entire treatment period (except at the 5th oGTT), while differences were only erratically 
observed between WT and RIPHAT treatment groups (see table 3).  
No differences between the RIPHAT groups were observed before 22 weeks of 
treatment. At the 5th and the 6th oGTT, however, the treatment showed some effect 
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because the FG in RIPHAT-PBS rats was significantly increased compared to RIPHAT-
3 mg/kg rats. Significant differences were also observed between RIPHAT-PBS and 
RIPHAT-1 mg/kg groups starting after 34 weeks of treatment (at the 8th oGTT) until the 
end of the study. The FG of RIPHAT-PBS and RIPHAT-10 mg/kg groups differed 
significantly only at the end of the study after 41 weeks of treatment. However, no 
significant differences in FG were seen between the three antibody-treatment dose 
groups at any time-point (see table 3 and figure 13a). 
Table 3: Fasting glucose (FG) and non-fasting glucose (NFG) of WT and RIPHAT 
rats at different time-points of treatment. All RIPHAT rats had significantly elevated 
FG and NFG levels compared to WT rats during the entire study (except at 5th oGTT). 
However, all antibody-treated RIPHAT rats (RIPHAT-1 mg/kg, RIPHAT-3 mg/kg, 
RIPHAT-10 mg/kg) showed lower FG and NFG levels compared to RIPHAT-PBS 
control rats with significantly decreased values at several time-points. See legend of the 
symbols for significant differences. 
Weeks of 
treatment 
WT 
(mmol/L) 
RIPHAT-
PBS 
(mmol/L) 
RIPHAT-
1mg/kg 
(mmol/L) 
RIPHAT-
3mg/kg 
(mmol/L) 
RIPHAT-
10mg/kg 
(mmol/L) 
Significances 
0 6.8±0.2 8.0±0.2 7.8±0.2 7.9±0.2 7.7±0.3 ϕϕ, μ 
8 6.5±0.2 7.8±0.3 7.3±0.3 7.5±0.3 7.3±0.3 ϕ  
14 6.8±0.2 8.2±0.2 7.2±0.4 7.9±0.3 7.7±0.3 ϕ 
18 7.2±0.3 8.5±0.3 7.9±0.2 8.3±0.2 8.3±0.3 ϕϕ, μ, ω 
22 7.1±0.2 8.2±0.3 7.3±0.3 7.2±0.3 7.3±0.2 λ 
26 6.6±0.2 8.7±0.3 8.3±0.3 7.7±0.3 8.1±0.4 ϕϕϕϕ, γγ, ωω, λ 
28 6.3±0.3 8.5±0.4 7.6±0.3 8.2±0.6 8.2±0.5 ϕϕ, μ 
30 6.4±0.2 9.4±0.7 7.7±0.3 8.1±0.7 8.1±0.6 ϕϕ  
32 5.9±0.2 10.0±1.1 7.4±0.5 8.4±0.9 8.4±0.7 ϕϕ  
34 6.6±0.3 11.4±1.0 8.0±0.6 10.2±1.0 9.8±1.0 ϕϕ, * 
39 6.7±0.3 14.7±1.3 10.2±1.1 11.9±1.5 10.7±1.2 ϕϕϕ, μ, * 
41 6.2±0.8 14.7±1.5 10.2±1.3 12.6±1.9 9.6±1.3 ϕϕϕ, μ, δ 
41 NFG 10.4±0.4 37.8±4.1 25.7±3.5 27.8±4.3 23.8±3.2 ϕϕϕϕ, γ, µ, ω 
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6.3.2 Fasting insulin levels 
Fasting plasma insulin levels (FI) in WT rats were higher than in RIPHAT rats at all 
time-points but the difference reached significance only at the 2nd oGTT and again 
from the 6th oGTT until sacrifice (see table 4 and figure 13b).  
FI in all RIPHAT rats remained similar from the 2nd until the 8th oGTT and at sacrifice 
and therefore, no significant differences in FI between the four RIPHAT groups were 
seen at these time-points of the experimental period (see table 4). However, all three 
antibody treated RIPHAT groups showed a strong tendency towards higher FI levels at 
the 9th oGTT and non-fasting insulin levels (NFI), measured at sacrifice, in comparison 
with RIPHAT-PBS control rats (see table 4 and figure 13b).  
Table 4: Fasting insulin (FI) and non-fasting insulin levels (NFI) of WT and 
RIPHAT rats at different time-points of treatment. Over the entire experimental 
period, WT rats showed higher FI and NFI levels compared to all RIPHAT rats. The 
four RIPHAT groups had constant and similar FI levels from 2nd until 8th oGTT and at 
sacrifice. But FI levels at 9th oGTT and NFI levels at sacrifice of RIPHAT-PBS rats 
tended to be lower compared to all antibody-treated RIPHAT rats (RIPHAT-1 mg/kg, 
RIPHAT-3 mg/kg, RIPHAT-10 mg/kg). See legend of the symbols for significant 
differences. 
Weeks of 
treatment 
WT 
(µg/L) 
RIPHAT-
PBS 
(µg/L) 
RIPHAT-
1mg/kg 
(µg/L) 
RIPHAT-
3mg/kg 
(µg/L) 
RIPHAT-
10mg/kg 
(µg/L) 
Significances 
8 0.28±0.03 0.18±0.01 0.16±0.01 0.18±0.01 0.22±0.02 ϕϕϕ, γγγγ, μμμ 
14 0.27±0.02 0.19±0.02 0.18±0.02 0.17±0.01 0.22±0.04  
18 0.27±0.02 0.20±0.02 0.19±0.01 0.22±0.04 0.20±0.02  
22 0.33±0.03 0.29±0.03 0.25±0.01 0.27±0.01 0.30±0.01  
26 0.44±0.10 0.22±0.02 0.19±0.02 0.20±0.02 0.23±0.05 ϕ, γγ, μμ, ω 
30 0.4±0.04 0.27±0.06 0.20±0.02 0.21±0.03 0.21±0.03 γγ, μμ, ωω 
34 0.29±0.05 0.19±0.03 0.18±0.02 0.17±0.02 0.16±0.02 ω 
39 0.44±0.08 0.13±0.02 0.21±0.03 0.21±0.05 0.21±0.04 ϕϕϕ, γγ, μμ, ωω 
41 0.44±0.08 0.17±0.01 0.19±0.01 0.17±0.01 0.19±0.01 ϕϕϕϕ, γγγγ, μμμμ, 
ωωωω 
41 NFI 7.0±0.4  1.4 ±0.5 2.7±0.5 2.7±0.7 2.7±0.6 ϕϕϕϕ, γγγγ, μμμμ, 
ωωωω 
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Figure 13: Fasting and non-fasting levels of glucose and insulin of RIPHAT and WT 
rats at 1st, 6th and 9th oGTT and at sacrifice. See legend of the symbols for significant 
differences.  
a) Glucose levels: Dotted black line indicates the average level of glycemia in WT rats.
Fasting glucose (FG) of WT rats was lower compared to RIPHAT rats during the entire 
experimental period and also non-fasting glucose (NFG) of WT rats at sacrifice was 
reduced compared to RIPHAT rats. At 1st oGTT, FG of all RIPHAT rats was similar. 
Until the end of the study, FG levels in all RIPHAT rats, especially in RIPHAT(tg)-PBS 
rats, increased over time. FG levels at 6th and 9th oGTT and at sacrifice as well as NFG 
levels at sacrifice of RIPHAT(tg)-PBS rats were higher compared to antibody-treated 
RIPHAT groups (RIPHAT(tg)-1mg/kg, RIPHAT(tg)-3 mg/kg, RIPHAT(tg)-10 mg/kg).  
b) Insulin levels: Fasting insulin (FI) and non-fasting insulin (NFI) was higher in WT
rats compared to RIPHAT rats at all time-points. FI levels of RIPHAT rats were similar 
at almost all time-points of the study, however, FI levels at 9th oGTT and NFI levels at 
sacrifice tended to be reduced in RIPHAT (tg)-PBS rats.  
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6.4 Blood levels during the oGTTs 
6.4.1 Glucose levels 
During the 1st oGTT before the beginning of the weekly antibody treatment, RIPHAT 
rats had already an impaired glucose tolerance compared to WT rats (see figure 14a). 
All treatment groups of RIPHAT rats showed similar baseline glycemia and glucose 
AUC levels during the 1st oGTT (see tables 5 and 6 and figure 14a).  
During the entire experimental period, glucose intolerance progressed over time in the 
RIPHAT-PBS control group compared to WT rats. The progression of glucose 
intolerance was less severe in all RIPHAT rats which received the antibody treatment, 
especially in RIPHAT-1 mg/kg and RIPHAT-10 mg/kg groups (see table 5), 
nonetheless, their glucose curves remained elevated compared to WT rats at all time 
points (see figure 14a). 
Differences in the glucose tolerance between the transgenic groups were seen first after 
8 weeks of treatment during the 2nd oGTT, with the RIPHAT-10 mg/kg rats having 
lower blood glucose values at 30, 60 and 120 min compared to the control RIPHAT 
group (see table 5). In both RIPHAT-1 mg/kg and RIPHAT-10 mg/kg groups, glucose 
curves and AUC of glucose differed significantly compared to RIPHAT-PBS control 
rats from the 3rd until the 8th oGTT (see tables 5 and 6 and figure 14a). The 
progression of glucose intolerance was less influenced in the RIPHAT-3 mg/kg group 
compared to the RIPHAT-PBS control group, and differences in glucose values 
between the two groups were seen only during the 6th oGTT (see tables 5 and 6 and 
figure 14a). 
Surprisingly, significant differences in the glucose AUC and the glucose curves were no 
longer observed during the last, 9th oGTT (see tables 5 and 6 and figure 14a) between 
any RIPHAT treatment group and their transgenic controls, though the AUC of glucose 
over time was significantly reduced in RIPHAT-1 mg/kg and RIPHAT-10 mg/kg rats 
compared to controls (see figure 15a).  
Based on the AUC of glucose and the glucose curves, no significant differences were 
seen between the three antibody-treated RIPHAT groups during the entire experimental 
period (see tables 5 and 6 and figures 14a and 15a). 
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Table 5: Glucose levels of RIPHAT rats at different oGTTs at 0, 15, 30, 60, 120 and 
240 minutes. All RIPHAT rats had similar glucose values before the start of any 
treatment at 1st oGTT. From the 2nd until the 9th oGTT, RIPHAT-PBS group showed the 
highest glucose levels, with significant differences (see legend of the symbols) 
compared to the antibody-treated RIPHAT groups (RIPHAT-1mg/kg, RIPHAT-3 
mg/kg, RIPHAT-10 mg/kg) at different time-points of several oGTTs. 
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Weeks of 
treatment 
Time-
point 
(min) 
RIPHAT-
PBS 
(mmol/L) 
RIPHAT-
1mg/kg 
(mmol/L) 
RIPHAT-
3mg/kg 
(mmol/L) 
RIPHAT-
10mg/kg 
(mmol/L) 
Significances 
0 0 8.0 7.8 8.0 7.7 
(1st oGTT) 15 12.0 11.9 11.8 11.9 
30 13.3 13.3 13.1 13.4 
60 12.6 13.0 12.2 12.6 
120 10.3 10.2 10.8 10.5 
240 9.6 8.8 9.3 9.3 
8 0 7.8 7.3 7.5 7.3 
(2nd oGTT) 15 13.4 12.2 13.0 12.4 
30 15.8 14.0 14.2 13.5 δ 
60 15.4 13.2 14.5 12.9 δ 
120 12.3 10.4 11.2 9.9 δ 
240 8.6 7.8 7.9 8.5 
14 0 8.2 7.2 7.9 7.7 
(3rd oGTT) 15 14.4 12.9 13.6 13.1 
30 16.4 14.0 14.4 14.1 *, δ 
60 17.0 14.3 15.4 13.7 **, δδδ 
120 13.8 10.7 11.8 10.8 ***, δδ 
240 9.3 8.5 9.1 9.3 
18 0 8.5 7.9 8.3 8.3 
(4th oGTT) 15 15.6 13.9 13.9 13.6 
30 17.2 14.9 15.2 14.7 *, δ 
60 17.1 14.9 15.8 14.5 δ 
120 14.2 12.1 12.3 11.6 δ 
240 10.3 8.4 9.5 9.5 
22 0 8.2 7.3 7.2 7.3 
(5th oGTT) 15 15.4 13.6 13.9 13.1 
30 16.7 14.6 15.1 14.4 
60 17.6 14.8 15.6 14.5 *, δ 
120 15.0 11.7 13.2 11.8 **, δδ 
240 10.6 8.0 9.3 9.4 * 
26 0 8.7 8.3 7.7 8.1 
(6th oGTT) 15 16.4 13.8 14.0 14.0 
30 18.0 15.0 14.9 15.2 *, λ 
60 18.1 15.0 15.5 14.9 *, δ 
120 15.4 12.2 13.8 11.8 *, δ 
240 12.4 8.0 10.3 10.3 *** 
30 0 9.4 7.7 8.1 8.1 
(7th oGTT) 15 18.1 14.5 14.8 14.5 
30 19.1 15.7 15.6 14.8 δ 
60 19.7 15.4 16.7 14.8 *, δδ 
120 16..9 13.5 14.9. 12.8 δ 
240 14.2 9.4 11.9 11.2 ** 
34 0 11.4 8.0 10.2 9.8 
(8th oGTT) 15 22.0 16.6 18.3 17.4 * 
30 24.5 19.0 21.3 19.2 *, δ 
60 23.8 17.8 21.0 19.0 ** 
120 21.6 15.8 17.7 15.9 *, δ 
240 18.4 12.5 15.0 13.4 * 
39 0 14.7 10.2 11.9 10.7 
(9th oGTT) 15 23.3 18.2 19.1 18.1 
30 24.8 20.1 20.9 19.7 
60 24.0 19.0 20.4 19.5 
120 22.0 17.1 18.7 17.5 
240 18.4 14.4 15.5 13.3 
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Table 6: Area under curve (AUC) of glucose at different time-points during the 
experimental period. All RIPHAT groups showed similar AUC before the start of any 
treatment at 1st oGTT (time-point 0). From the 2nd until the 9th oGTT, RIPHAT-PBS 
rats showed the highest AUC, with significantly reduced AUC in RIPHAT-1 mg/kg and 
RIPHAT-10 mg/kg groups at several time-points. See legend of the symbols for 
significant differences. 
Weeks of 
treatment 
RIPHAT-
PBS 
(mM.min-1) 
RIPHAT-
1mg/kg 
(mM.min-1) 
RIPHAT-
3mg/kg 
(mM.min-1) 
RIPHAT-
10mg/kg 
(mM.min-1) 
Significances 
0 2610±75 2564±88 2609±70 2610±118 
8 2937±113 2551±119 2712±112 2519±106 *, δ 
14 3190±147 2647±142 2892±125 2678±126 *, δ 
18 3348±141 2862±126 2998±96 2867±148 *, δ 
22 3443±172 2788±139 3042±133 2857±168 **, δ 
26 3662±235 2855±156 3164±170 2968±192 **, δ 
30 4029±276 3101±212 3443±213 3099±263 *, δ 
34 5077±318 3703±276 4265±334 3856±315 **, δ 
39 5182±307 4060±343 4381±371 4048±337 
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Figure 14: Glucose and insulin curves of all rats at 1st, 6th and 9th oGTT. See legend of 
the symbols for significant differences.  
a) Glucose curves: All RIPHAT rats showed similar glucose curves at 1st oGTT before
the start of any treatment. At 6th and 9th oGTT, RIPHAT-PBS control rats revealed the 
highest glucose values with significantly elevated glucose levels compared to the 
antibody-treated RIPHAT rats at different time-points of the 6th oGTT.  
b) Insulin curves: Insulin levels of all RIPHAT rats were similar at 6th oGTT. At 9th
oGTT, insulin levels of RIPHAT-PBS rats were lower compared to RIPHAT-1 mg/kg 
group.  
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6.4.2 Insulin levels 
Reflecting the progressive decrease in β-cell function, the AUC of insulin during the 
oGTT decreased over time in the PBS control group. In fact, the AUC of insulin was 
significantly lower (p<0.001) at the end of the study than it was at the 2nd oGTT (see 
table 8 and figure 15b).  
During the 2nd and 3rd oGTT, insulin values were significantly reduced in RIPHAT-PBS 
rats compared to RIPHAT-10 mg/kg rats while during the last three oGTTs, differences 
in plasma insulin levels became significant in comparison with RIPHAT-1 mg/kg rats 
(see table 7 and figure 14b).  
However, neither the AUC of insulin nor the insulin concentrations at specific times 
during the oGTT were significantly different between the three antibody treated 
RIPHAT groups during the entire experimental period (see tables 7 and 8 and figures 
14b and 15b).  
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Table 7: Insulin levels from the 2nd until the 9th oGTT at 0, 15, 30, 60, 120 and 240 
minutes. At the 2nd and the 3rd oGTT, RIPHAT-10 mg/kg group had elevated insulin 
values compared to RIPHAT-PBS rats. At 7th, 8th and 9th oGTT, RIPHAT-1 mg/kg rats 
showed higher insulin levels compared to RIPHAT-PBS rats. See legend of the symbols 
for significant differences. 
Weeks of 
treatment 
Time-
point 
(min) 
RIPHAT-
PBS 
(µg/L) 
RIPHAT-
1mg/kg 
(µg/L) 
RIPHAT-
3mg/kg 
(µg/L) 
RIPHAT-
10mg/kg 
(µg/L) 
Significances 
8 0 0.18 0.16 0.18 0.22 
(2nd oGTT) 15 0.33 0.34 0.35 0.52 δδ 
30 0.17 0.19 0.17 0.28 
60 0.33 0.31 0.32 0.40 
120 0.38 0.37 0.40 0.56 δδ 
240 0.34 0.30 0.33 0.45 
14 0 0.19 0.18 0.17 0.23 
(3rd oGTT) 15 0.26 0.36 0.34 0.46 δ 
30 0.23 0.30 0.27 0.32 
60 0.41 0.48 0.43 0.53 
120 0.51 0.52 0.46 0.64 
240 0.45 0.45 0.49 0.66 δ 
18 0 0.21 0.19 0.23 0.20 
(4th oGTT) 15 0.31 0.35 0.31 0.35 
30 0.20 0.25 0.21 0.22 
60 0.29 0.35 0.32 0.32 
120 0.39 0.39 0.45 0.43 
240 0.39 0.42 0.46 0.48 
22 0 0.29 0.25 0.27 0.30 
(5th oGTT) 15 0.34 0.33 0.38 0.32 
30 0.24 0.26 0.27 0.25 
60 0.33 0.33 0.31 0.33 
120 0.47 0.41 0.43 0.40 
240 0.41 0.45 0.41 0.47 
26 0 0.22 0.19 0.20 0.23 
(6th oGTT) 15 0.32 0.43 0.42 0.55 
30 0.23 0.27 0.26 0.27 
60 0.32 0.39 0.37 0.38 
120 0.39 0.45 0.40 0.49 
240 0.41 0.45 0.60 0.64 
30 0 0.27 0.20 0.21 0.21 
(7th oGTT) 15 0.29 0.34 0.34 0.35 
30 0.18 0.25 0.22 0.24 
60 0.32 0.39 0.34 0.37 
120 0.36 0.59 0.50 0.51 * 
240 0.44 0.49 0.46 0.51 
34 0 0.19 0.18 0.17 0.16 
(8th oGTT) 15 0.24 0.30 0.30 0.28 
30 0.17 0.21 0.20 0.17 
60 0.30 0.34 0.32 0.32 
120 0.25 0.41 0.33 0.35 * 
240 0.30 0.35 0.35 0.40 
39 0 0.13 0.21 0.27 0.21 
(9th oGTT) 15 0.17 0.38 0.29 0.31 * 
30 0.14 0.22 0.19 0.22 
60 0.18 0.36 0.26 0.26 
120 0.22 0.41 0.36 0.37 
240 0.25 0.40 0.41 0.43 
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Table 8: Area under curve (AUC) of insulin in RIPHAT rats at different time-points 
of the experimental period. While antibody-treated RIPHAT rats (RIPHAT-1 mg/kg, 
RIPHAT-3 mg/kg and RIPHAT-10 mg/kg) maintained stable AUCs from 2nd until 9th 
oGTT, the AUC of RIPHAT-PBS rats decreased over time, with lowest AUC at the end 
of the study (t-test of insulin AUC at 2nd oGTT and insulin AUC at 9th oGTT: p<0.001). 
See legend of the symbols for significant differences. 
Weeks of 
treatment 
RIPHAT-
PBS 
(µg/L.min-1)
RIPHAT-
1mg/kg 
(µg/L.min-1) 
RIPHAT-
3mg/kg 
(µg/L.min-1) 
RIPHAT-
10mg/kg 
(µg/L.min-1) 
Significances 
8 79.3±5.0 75.2±5.1 81.0±8.8 111.4±12.6 δ 
14 102.2±8.4 108.9±9.6 102.1±9.2 136.8±13.3 
18 82.1±6.3 87.8±7.6 93.7±13.7 94.2±10.5 
22 94.9±8.8 91.5±6.9 90.4±9.8 92.2±7.8 
26 84.8±9.4 98.8±12.5 102.8±14.0 115.6±16.5 
30 83.4±10.1 112.1±14.4 99.3±14.7 105.4±10.9 
34 62.9±9.5 84.1±8.7 75.8±10.7 79.0±10.9 
39 49.4±5.9 89.3±13.1 78.5±12.7 81.7±11.6 * 
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Figure 15: AUC of glucose and insulin over time in RIPHAT rats. While AUC of 
glucose in RIPHAT(tg)-PBS rats increased at its most, AUC of insulin in RIPHAT(tg)-
PBS rats decreased over time. See legend of the symbols for significant differences.  
a) Glucose AUC from 1st until 9th oGTT: AUC of glucose increased in all four
RIPHAT groups over time. RIPHAT(tg)-PBS rats showed the highest AUC during all 
oGTTs, with significant differences compared to all antibody-treated RIPHAT rats 
(RIPHAT(tg)-1 mg/kg, RIPHAT(tg)-3 mg/kg, RIPHAT(tg)-10 mg/kg) at several time-
points, especially at the end of the study.  
b) Insulin AUC from 2nd until 9th oGTT: AUC of insulin in RIPHAT rats which
received antibody treatment (RIPHAT-1 mg/kg, RIPHAT-3 mg/kg, RIPHAT-10 mg/kg) 
remained stable while AUC of RIPHAT(tg)-PBS rats significantly decreased until the 
end of the study (t-test of insulin AUC at 2nd oGTT and insulin AUC at 9th oGTT: 
p<0.001).  
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7 Discussion 
The aim of our study was to determine the most effective dose (1, 3 or 10 mg/kg) of a 
human-derived antibody targeting toxic hIAPP oligomers in RIPHAT rats, a transgenic 
rat model of T2DM expressing hIAPP [66]. After 41 weeks of treatment with the 
antibody NI-203.26C11-r, all doses showed a significant effect in slowing the 
progression of T2DM in RIPHAT rats compared to PBS-treated RIPHAT controls 
based on glucose and insulin levels during the oGTTs, although no dose-dependent 
effects of NI-203.26C11-r were observed at the end of the experimental period. 
Human T2DM is characterized by insulin resistance, defective insulin secretion due to 
failure and loss of pancreatic β-cells and by the deposition of islet amyloid derived from 
IAPP. Compensatory mechanisms of insulin resistance initially cause an increase in β-
cell mass with enhanced insulin secretion [6]. Because IAPP is stored and co-secreted 
with insulin by the β-cells, an increase in insulin secretion also leads to an increase in 
IAPP secretion. Elevated IAPP concentrations in the secretory vesicles of β-cells favour 
the intracellular formation of small toxic IAPP oligomers, finally resulting in 
extracellular amyloid deposits as seen in over 90% of T2DM patients [6], [37], [41]. 
Toxic oligomers of IAPP cause β-cell failure and death via different mechanisms such 
as inflammation and membrane disruption [38], [47]. Therefore, treatment against toxic 
IAPP oligomers and islet amyloid deposits in diabetic patients is a very promising 
approach for the therapy of T2DM. 
In contrast to humans, the formation of toxic IAPP oligomers does not occur in rodents 
because of the presence of three proline residues which act as β-sheet breakers in the 
amyloidogenic region of IAPP, i.e. between amino acids 20 and 29 of the 37 amino acid 
peptide (IAPP20-29) [35], [46]. Due to these small but important differences in the 
primary structure of IAPP among species, a transgenic rat model producing hIAPP in β-
cells (RIPHAT rats) has been created to study the pathological mechanisms of T2DM, 
including the deposition of small toxic oligomers and islet amyloid in rodents [59], [66]. 
RIPHAT rats were used in the current study (HIP3) and in two previous studies (HIP1 
and HIP2) to test the therapeutic efficacy and to establish the dose-dependent effect of 
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the NI-203.26C11-r antibody. This antibody has been demonstrated to bind only to 
pathologically misfolded but not to physiological monomeric forms of human and rat 
IAPP (Data from Neurimmune). RIPHAT rats represent a model of T2DM with 
impaired glucose tolerance around 3 months of age and a diabetic phenotype between 5 
to 10 months of age; the diabetic phenotype is mainly due to the defect in insulin 
secretion, not insulin resistance.  
In the previous studies (HIP1 and HIP2) conducted by our group in collaboration with 
Neurimmune AG, the 28 week administration of 3 mg/kg of the NI-203.26C11-r 
antibody was safe and resulted in improved glucose tolerance, enhanced β-cell function, 
decreased hyperglycemia, elevated plasma insulin levels, preserved β-cell content and 
normalized BW gain in RIPHAT rats [98], [99]. These findings were generally 
confirmed in the current dose-response study (HIP3), where we compared the effects of 
the 3 mg/kg dose to a lower (1 mg/kg) and a higher (10 mg/kg) dose of NI-203.26C11-r. 
RIPHAT rats treated with PBS served as control. To exclude any unspecific effect of 
our antibody in healthy, non-transgenic rats, WT rats received similar treatment options 
as the RIPHAT rats.  
In the current HIP3 study, the even longer administration (41 weeks) of a higher dose 
(10 mg/kg) of the NI-203.26C11-r antibody was safe and had no side effects in both 
RIPHAT and WT rats. The observed beneficial effects basically recapitulated our 
previous findings because NI-203.26C11-r increased the well-being of treated RIPHAT 
rats, i.e. BW increased and reached a plateau during the last four months of the 
experimental period at all doses tested while RIPHAT-PBS control rats lost weight 
during the last months of the study. The latter was most likely due to the development 
of a severe diabetic phenotype characterized by polyuria and polydipisa (PU/PD). 
Interestingly, only RIPHAT rats receiving the lower antibody-dose showed a 
significantly higher BW gain compared to RIPHAT-PBS rats. Hence, although no 
significant differences were seen among the three different antibody dose groups, the 
RIPHAT-1 mg/kg rats tended to gain more weight compared to the other two treatment 
groups at the end of the study.  
Fasting glucose (FG) levels in WT rats did not change and were lower compared to the 
RIPHAT groups during the entire experimental period. As expected, RIPHAT-PBS rats 
showed highest FG values among all transgenic rats, and the difference became 
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significant after 22 weeks (RIPHAT-3 mg/kg group), 34 weeks (RIPHAT-1 mg/kg 
group) or 41 weeks (RIPHAT-10 mg/kg group) of treatment, respectively. At sacrifice, 
the RIPHAT-10 mg/kg rats also showed significantly lower non-fasting glucose (NFG) 
levels compared to the control group. Therefore, consistent with the findings in the 
HIP2 study [99], these results showed a clear effect of the antibody in reducing FG as 
well as the NFG in RIPHAT rats.  
Glucose intolerance in RIPHAT rats is caused by decreased β-cell mass due to toxic 
hIAPP oligomers which ultimately results in reduced insulin-secretion [6], [7], [66]. 
Thus, it is not surprising that WT rats containing a normal amount of β-cells had higher 
fasting insulin (FI) levels at all time-points as well as higher non-fasting insulin (NFI) 
levels than RIPHAT rats. Since the major function of insulin is to lower the blood 
glucose levels after it raises [11], NFI might serve as a better indicator of glucose 
intolerance than FI levels. In antibody-treated RIPHAT rats, FI levels at the 9th oGTT 
(i.e. after 39 weeks of treatment) and NFI levels at sacrifice were almost twice as high 
than in PBS-treated control rats, although differences were not significant. The higher 
FI and NFI levels in the antibody-treated RIPHAT rats compared to the PBS-treated 
control group might result from the protective effects of NI-203.26C11-r on pancreatic 
β-cells in reducing the aggregation of toxic hIAPP. This explanation is supported by the 
histological findings of the HIP2 study [99], where the β-cell content in antibody-treated 
RIPHAT rats was significantly larger than in PBS-treated RIPHAT control rats.  
As expected in this rat model, all RIPHAT rats already showed a mild glucose 
intolerance during the first oGTT before the start of any treatment, i.e. at 12 weeks of 
age. While RIPHAT-PBS rats showed a strong progression of glucose intolerance 
during the experiments, the impairment of glucose tolerance was less severe in the 
antibody-treated RIPHAT rats. Although differences in glucose levels during the nine 
oGTTs were not consistently observed, overall the AUCs of glucose were lower in 
RIPHAT-1 mg/kg and RIPHAT 10/mg/kg groups compared to the control rats from the 
2nd until the 8th oGTT. Differences between the RIPHAT-3 mg/kg rats and the PBS-
control rats during the oGTTs became significant only after 34 weeks of treatment. To 
assess differences between the three antibody-treated dose groups, delta-values of each 
single dose group and the PBS-control group of the glucose and insulin results of the 
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study were compared by using a one-way ANOVA. Delta-values showed no significant 
differences in glucose levels and glucose AUCs among the three dose groups. 
During the oGTTs of the first three months of the study, the RIPHAT-10 mg/kg group 
clearly showed higher insulin values compared to the other RIPHAT groups although 
differences were significant only when compared to RIPHAT-PBS rats. After 3 months 
of treatment, insulin levels in the RIPHAT-10 mg/kg group dropped to the levels 
observed in the RIPHAT-1 mg/kg and RIPHAT-3 mg/kg groups and were maintained 
stable until the end of the study. This trend might be explained by the fact that the 
highest dose of the NI-203.26C11-r antibody had the strongest protective effect against 
toxic hIAPP species during the initial stage of hIAPP aggregation but that with 
increasing amounts of aggregated hIAPP, the effect was no longer stronger than in the 
other antibody-treated RIPHAT groups. All antibody-treated RIPHAT groups showed 
higher insulin levels compared to RIPHAT-PBS rats whose insulin levels progressively 
decreased during the last four months of the study. This finding suggests a protective 
effect of the NI-203.26C11-r antibody on β-cells and insulin secretion. Despite higher 
insulin levels in the RIPHAT-10 mg/kg group at the beginning of the study, the 
comparison of the delta-values of the insulin results during the study showed no 
differences among the three dose groups.  
To reduce an anti-antibody response against the human-derived antibody NI-203.26C11 
in rats, a rat chimeric version (-r) with human variable domains and rat constant regions 
was produced at Neurimmune and used in this study. Nonetheless, an anti- NI-
203.26C11-r antibody response that was proportional to the dose of NI-203.26C11-r 
injected was detected in RIPHAT rats (Data from Neurimmune; results not shown). 
These anti-NI-203.26C11-r antibodies might be the reason for the lack of a clear dose-
dependent response in the HIP3 study because the anti-antibodies may have partly 
inhibited the effect of the NI-203.26C11-r antibody. 
A limitation of the RIPHAT rat model is the fact that the rats do not develop insulin 
resistance which is an important component of most cases of T2DM in obese patients 
[12]. Hence, even though RIPHAT rats are a very useful model to study hIAPP 
aggregates in diabetes research, these rats do not fully mimic all aspects of the disease 
in humans.  
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Another potential drawback of pre-clinical studies performed in laboratory rodents is 
the variability and the potential appearance of (side-) effects of a compound when this is 
then tested in a different species. As for an example, the humanized antibody 
Bapineuzumab, which, despite its promising effect shown in mice in targeting the 
amyloid deposits derived from amyloid-β (Aβ) [100], lead to vasogenic edemas when 
tested in humans [101], [102], [103], [104]. Bapineuzumab was, however, a murine 
antibody that was humanized for the application in human patients. On the contrary, the 
antibody NI-203.26C11 is an antibody recombinantly produced from a human-derived 
antibody. We, therefore, do not expect similar drawbacks when NI-203.26C11 will be 
tested in humans in future clinical trials.  
In summary, we demonstrated that all three tested doses of NI-203.26C11-r reduced 
hyperglycemia, improved glucose tolerance and increased plasma insulin levels and the 
low dose (1 mg/kg) even normalized BW gain. More significant differences in the AUC 
of glucose and in the insulin levels measured during the oGTTs were shown between 
the 1 mg/kg and the 10 mg/kg doses than in the 3 mg/kg dose compared to the controls. 
Thus, there seems to be a tendency for the low and the high antibody dose to be more 
effective in slowing the progression of T2DM in RIPHAT rats than the middle dose of 3 
mg/kg. 
Our finding that a low dose of 1 mg/kg of the antibody NI-203.26C11-r was at least as 
effective in slowing the progression of T2DM as a higher dose, also indicates that this 
dose may be sufficient for future clinical tests, reducing the potential risk for side 
effects as well as the higher costs when using higher doses. Further, it would be 
important to investigate whether even lower doses than 1 mg/kg may be sufficient to 
successfully slow the progression of T2DM in transgenic RIPHAT rats.  
Currently, the histological examination of the pancreatic tissues of all RIPHAT and WT 
rats of the HIP3 study is ongoing. These additional results will add further evidences in 
respect to the mechanisms of action of NI-203.26C11-r in RIPHAT rats. A follow-up 
study has been initiated to evaluate the efficacy of a combination therapy of NI-
203.26C11-r together with metformin, which is a first-line-therapy to lower blood 
glucose levels in diabetic human patients [67]. 
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To conclude, passive immunization targeting IAPP aggregates with the antibody NI-
203.26C11 is a very promising approach to treat T2DM. 
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